Tacrolimus pharmacokinetics are influenced by CYP3A5 , age, and concomitant fluconazole in pediatric kidney transplant patients
Clinical and Translational Science · 2023-10 · 16 (10) · 1768-1778
DOI: 10.1111/cts.13571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 26.06.2023. Verfasst von Alaa Alghamdi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Tacrolimus, the most common immunosuppressant for organ transplant, has a narrow therapeutic range and is metabolized by CYP3A4/5. Trough concentration monitoring and dosing adjustments are used to reach a therapeutic range. CYP3A5 intermediate and normal metabolizers (*1 allele carriers; IM/NM) demonstrate faster tacrolimus metabolism than poor metabolizers (PM). We analyzed the electronic health records of 93 patients aged 150% of the required daily dose compared with PM. The concentration/dose ratio was influenced by age and concomitant fluconazole ( p = 0.0003, p = 0.034, respectively) and the average daily dose decreases with age in CYP3A5 PM ( p = 0.001). Tremors were more common in patients who ever had a trough concentration >15 ng/mL compared with those who never had a trough concentration >15 ng/mL (OR 3.31, 95% CI 1.03–8.98, p = 0.038). Using standard dosing, CYP3A5 IM/NM took longer to reach the goal range and require more dose adjustments and higher doses than PM. Preemptive genotyping could decrease the number of dose changes necessary to reach a therapeutic dose. We have implemented pre‐transplant CYP3A5 testing at our institution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- Department of Chemistry, Virginia Tech Center for Drug Discovery, Blacksburg, Virginia, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Division of Nephrology & Hypertension, James M. Anderson Center fo Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
ORCID-Profile: David K Hooper, Tomoyuki Mizuno, Laura B Ramsey
Förderung
- NCATS NIH HHS
Zitieren
APA
Alghamdi, A., Seay, S., Hooper, D. K., Varnell, C. D., Darland, L., Mizuno, T., Lazear, D., & Ramsey, L. B. (2023). Tacrolimus pharmacokinetics are influenced by CYP3A5 , age, and concomitant fluconazole in pediatric kidney transplant patients. Clinical and Translational Science, 16(10), 1768-1778. https://doi.org/10.1111/cts.13571
Vancouver
Alghamdi A, Seay S, Hooper DK, Varnell CD, Darland L, Mizuno T, et al. Tacrolimus pharmacokinetics are influenced by CYP3A5 , age, and concomitant fluconazole in pediatric kidney transplant patients. Clinical and Translational Science. 2023;16(10):1768-1778. doi:10.1111/cts.13571
BibTeX
@article{Alghamdi2023,
author = {Alghamdi, Alaa and Seay, Sarah and Hooper, David K and Varnell, Charles D and Darland, Leanna and Mizuno, Tomoyuki and Lazear, Danielle and Ramsey, Laura B},
title = {Tacrolimus pharmacokinetics are influenced by CYP3A5 , age, and concomitant fluconazole in pediatric kidney transplant patients},
journal = {Clinical and Translational Science},
year = {2023},
volume = {16},
number = {10},
pages = {1768--1778},
doi = {10.1111/cts.13571}
}
EUVIMED